{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T05:59:09Z","timestamp":1648879149942},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.lpm.2008.10.002","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T08:17:21Z","timestamp":1226305041000},"page":"508-511","source":"Crossref","is-referenced-by-count":0,"title":["Et si c\u2019\u00e9tait une maladie rare\u00a0?"],"prefix":"10.1016","volume":"38","author":[{"given":"S\u00e9verine","family":"Guillaume-Czitrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Brauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karelle","family":"Benistan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique-Paul","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2008.10.002_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.lpm.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet."},{"key":"10.1016\/j.lpm.2008.10.002_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet."},{"key":"10.1016\/j.lpm.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/clinchem\/13.7.565","article-title":"Enzymatic abnormalities in diseases of sphingolipid metabolism","volume":"13","author":"Brady","year":"1967","journal-title":"Clin Chem"},{"key":"10.1016\/j.lpm.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2008.10.002_bib6","first-page":"S65","article-title":"Manifestations neurologiques de la maladie de Fabry","volume":"36 S1","author":"Clavelou","year":"2007","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2008.10.002_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.lpm.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.arcped.2007.02.090","article-title":"Aspects p\u00e9diatriques de la maladie de Fabry","volume":"14","author":"Roche","year":"2007","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.lpm.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jocd.2007.12.004","article-title":"Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions","volume":"11","author":"Bishop","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.lpm.2008.10.002_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lpm.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.lpm.2008.10.002_bib14","first-page":"S48","article-title":"Cardiomyopathies m\u00e9taboliques d\u2019origine g\u00e9n\u00e9tique","volume":"36 S1","author":"Germain","year":"2007","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2008.10.002_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2008.10.002_bib17","first-page":"S69","article-title":"Principe du d\u00e9veloppement d\u2019un m\u00e9dicament orphelin pour une maladie g\u00e9n\u00e9tique\u00a0: l\u2019exemple de l\u2019agalsidase b\u00eata","volume":"36 S1","author":"Germain","year":"2007","journal-title":"Presse Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498208005587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498208005587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T01:24:01Z","timestamp":1589073841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498208005587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0755498208005587"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2008.10.002","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}